The FHAB platform exhibits three pivotal characteristics in vivo: i) an enhanced t1⁄2 owing to the binding of albumin, ii) targeting of tumor tissue by binding to FcRn and GP60 receptors that are overexpressed in many solid tumors, and iii) retention in the acidic TME upon binding or rebinding to SPARC. This evidence concerns the gene ALB and neoplasm.